TG Therapeutics
TG Therapeutics
TGTX
NASDAQ
40.88
USD
0.10%
About
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb).
BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening.
TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 3.3M |
| Three Month Average Volume | 61.2M |
| High Low | |
| Fifty-Two Week High | 25.38 USD |
| Fifty-Two Week Low | 6.46 USD |
| Fifty-Two Week High Date | 21 Aug 2024 |
| Fifty-Two Week Low Date | 16 Oct 2023 |
| Price and Volume | |
| Current Price | 23.49 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | 20.19% |
| Thirteen Week Relative Price Change | 34.65% |
| Twenty-Six Week Relative Price Change | 18.95% |
| Fifty-Two Week Relative Price Change | 79.04% |
| Year-to-Date Relative Price Change | 16.14% |
| Price Change | |
| One Day Price Change | -0.09% |
| Thirteen Week Price Change | 44.11% |
| Twenty-Six Week Price Change | 30.79% |
| Five Day Price Change | -3.97% |
| Fifty-Two Week Price Change | 124.36% |
| Year-to-Date Price Change | 37.53% |
| Month-to-Date Price Change | 18.88% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1.05995 USD |
| Book Value Per Share (Most Recent Quarter) | 1.14684 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.05467 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.14684 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | 0.67484 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 1.57339 USD |
| Revenue Per Share (Trailing Twelve Months) | 2.29388 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | 0.08533 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | 0.6001 USD |
| Normalized (Last Fiscal Year) | 0.08533 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | 0.08927 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | 0.67099 USD |
| Including Extraordinary Items (Last Fiscal Year) | 0.08533 USD |
| Including Extraordinary Items (Trailing Twelve Months) | 0.6001 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.43641 USD |
| Cash Per Share (Most Recent Quarter) | 1.40314 USD |
| Cash Flow Per Share (Last Fiscal Year) | 0.08675 USD |
| Cash Flow Per Share (Trailing Twelve Months) | 0.6341 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | 0.44871 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -350 |
| Cash Flow Revenue (Trailing Twelve Months) | 20 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | 27.62% |
| Pretax Margin (Last Fiscal Year) | 5.59% |
| Pretax Margin (5 Year) | -404.87% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 93.95% |
| Gross Margin (Trailing Twelve Months) | 92.76% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | 8.83% |
| Operating Margin (Trailing Twelve Months) | 29.37% |
| Operating Margin (5 Year) | -394.19% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | 5.42% |
| Net Profit Margin (Trailing Twelve Months) | 27.60% |
| Net Profit Margin (5 Year) | -405.03% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 29.90% |
| Tangible Book Value (5 Year) | 47.04% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 357.05% |
| Revenue Growth (3 Year) | 333.86% |
| Revenue Change (Trailing Twelve Months) | 1,341.63% |
| Revenue Per Share Growth | 278.92% |
| Revenue Growth (5 Year) | 1,054.11% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | 331.41% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 112.82% |
| EPS Change (Trailing Twelve Months) | 147.36% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 23 |
| Price to Tangible Book (Most Recent Quarter) | 20 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | 54 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -114,715,000 |
| Net Debt (Last Fiscal Year) | -117,390,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 16 |
| Price to Sales (Trailing Twelve Months) | 10 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | 39 |
| PE Normalized (Last Fiscal Year) | 275 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | 27 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 1.2K |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 30 |
| PE Including Extraordinary Items (Trailing Twelve Months) | 39 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 22 |
| Price to Book (Most Recent Quarter) | 20 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 62 |
| Long Term Debt to Equity (Most Recent Quarter) | 58 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | 0.00% |
| Payout Ratio (Trailing Twelve Months) | 0.00% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 5 |
| Quick Ratio (Most Recent Quarter) | 3 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | 273 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | 37 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 6 |
| Current Ratio (Most Recent Quarter) | 4 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -31,413,000 |
| Free Cash Flow (Trailing Twelve Months) | 67.8M |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | 2 |
| Net Interest Coverage (Trailing Twelve Months) | 8 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 62 |
| Total Debt to Equity (Most Recent Quarter) | 58 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | 4.84% |
| Return on Assets (Trailing Twelve Months) | 30.76% |
| Return on Assets (5 Year) | -62.87% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | 11.57% |
| Return on Equity (Trailing Twelve Months) | 87.78% |
| Return on Equity (5 Year) | -104.23% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | 6.09% |
| Return on Investment (Trailing Twelve Months) | 43.42% |
| Return on Investment (5 Year) | -80.06% |